<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04498455</url>
  </required_header>
  <id_info>
    <org_study_id>1255329-5</org_study_id>
    <nct_id>NCT04498455</nct_id>
  </id_info>
  <brief_title>Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency</brief_title>
  <official_title>Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized placebo controlled trial to determine if increased dietary fiber will prevent&#xD;
      weight gain, inhibit adiposity and reduce perceived stress levels in residents at the Waco&#xD;
      Family Health Center as the result of changes in distal gut microbiota composition and&#xD;
      function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will utilize a single blind, placebo controlled, parallel design to assess the&#xD;
      effect of dietary fiber [Prebiotin] on the gut microbiome, perceived stress, anthropometric&#xD;
      variables, and clinical biomarkers of metabolism. All participants in this study will be&#xD;
      resident physicians at the Family Health Center in Waco, TX. This population was selected&#xD;
      based on pilot data indicating they are at a greater risk for weight gain and have higher&#xD;
      levels of stress than the average population. The goal is to recruit 40 participants for a 12&#xD;
      week intervention trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2018</start_date>
  <completion_date type="Actual">February 15, 2019</completion_date>
  <primary_completion_date type="Actual">February 14, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized placebo-controlled trial of a fiber supplement [Prebiotin] compared to placebo [maltodextrin]</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>The investigators will use the following procedure to assess the effect of Prebiotin (OEI) on changes in body weight: there will be two test days: a) baseline (Day 0), prior to randomization to OEI or placebo; and b) week 12, following the 11 week course of OEI/placebo treatment. The investigators will use OEI for the inulin challenge. Change in body weight will be quantified by bio electrical impedance.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Weight Gain Trajectory</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary Supplement: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prebiotin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary Supplement: Prebiotin (oligofructose enriched inulin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prebiotin</intervention_name>
    <description>Fructo-oligosaccharide dietary supplement powder</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Prebiotin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Currently a resident in training at the Family Health Center in their first year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Currently on prescribed metformin or NSAIDS&#xD;
&#xD;
          -  A diagnosed gastro-intestinal disease (i.e. irritable bowel syndrome or Crohn's&#xD;
             disease)&#xD;
&#xD;
          -  Known allergy to the supplement, placebo, or provided meal replacements&#xD;
&#xD;
          -  Antibiotic use within the last 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LesLee Funderburk, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor University</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76798</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://greathouselab.github.io/Fiber_Intervention_Study/</url>
    <description>Study analysis</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor University</investigator_affiliation>
    <investigator_full_name>Leigh Greathouse</investigator_full_name>
    <investigator_title>Assistant Professor of Nutrition Sciences</investigator_title>
  </responsible_party>
  <keyword>Fiber</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
    <mesh_term>Body-Weight Trajectory</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share individual data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

